Study of Serum Uric Acid Levels in Myocardial Infarction and Its Association With Killip Class

Maryam Mehrpooya1, Farnoosh Larti1, Younes Nozari2

  • 1Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Acta Medica Iranica
|March 12, 2017
PubMed

Insights

Elevated uric acid levels are linked to heart failure, particularly in ST-elevation myocardial infarction (STEMI) patients. Higher uric acid correlates with worse clinical status and disease severity in these individuals.

Area of Science:

  • Cardiology
  • Biochemistry
  • Internal Medicine

Background:

  • Heart failure (HF) is a complex clinical syndrome with significant morbidity and mortality.
  • Uric acid, a product of purine metabolism, has been implicated as a potential biomarker in cardiovascular diseases.
  • The relationship between uric acid levels and the severity of heart failure, especially in acute settings like STEMI, requires further elucidation.

Purpose of the Study:

  • To compare serum uric acid levels between patients with and without heart failure.
  • To investigate the association between uric acid levels and the clinical status (Killip class) in patients with ST-elevation myocardial infarction (STEMI).
  • To explore the correlation of uric acid with left ventricular (LV) systolic dysfunction and treatment strategies in STEMI.

Main Methods:

  • A case-control study involving 50 patients with acute heart failure and 50 controls.
  • Echocardiography was used for clinical assessment and documentation of heart failure.
  • Serum uric acid levels were measured and compared across different patient groups and clinical classifications.

Main Results:

  • Patients with heart failure exhibited significantly higher mean serum uric acid levels (7.6 mg/dL) compared to controls (4.5 mg/dL).
  • In STEMI patients, uric acid levels were markedly elevated (9.2 mg/dL) compared to non-STEMI heart failure patients (6.5 mg/dL).
  • Uric acid levels showed a significant positive correlation with Killip class, severity of LV systolic dysfunction, and were higher in STEMI patients requiring CABG versus PCI.

Conclusions:

  • Serum uric acid is significantly elevated in patients with heart failure, including those with STEMI.
  • Higher uric acid levels are associated with poorer clinical status (higher Killip class) and more severe LV systolic dysfunction in STEMI patients.
  • Uric acid may serve as a valuable biomarker for assessing disease severity and guiding treatment decisions in acute heart failure and STEMI.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.0K
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
393
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
276
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
353
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
520
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K